Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 49

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 49
---
 |     |      |     17,658 |   |
| Net loss                                                                                     |     |                          | (2,220,671 | ) |     |      | (2,035,834 | ) |
| Deemed dividends – make whole shares                                                         |     |                          | (1,231,900 | ) |     |      |          — |   |
| Deemed dividends-warrants                                                                    |     |                          |   (613,939 | ) |     |      |          — |   |
| Accrued dividends on preferred shares                                                        |     |                          |   (126,367 | ) |     |      |          — |   |
| Net loss attributable to common shareholders                                                 |     | $                        | (4,192,877 | ) |     | $    | (2,035,834 | ) |
| Basic and diluted net loss per common share                                                  |     | $                        |      (1.05 | ) |     | $    |      (1.94 | ) |
| Weighted average common shares used in computing basic and diluted net loss per common share |     |                          |  4,004,867 |   |     |      |  1,048,632 |   |
| COMPREHENSIVE LOSS                                                                           |     |                          |            |   |     |      |            |   |
| Other comprehensive loss:                                                                    |     |                          |            |   |     |      |            |   |
| Net loss                                                                                     |     | $                        | (2,220,671 | ) |     | $    | (2,035,834 | ) |
| Effect of exchange rate changes                                                              |     |                          |          — |   |     |      |    121,428 |   |
| Defined pension plan adjustments                                                             |     |                          |          — |   |     |      |     40,850 |   |
| Comprehensive loss                                                                           |     | $                        | (2,220,671 | ) |     | $    | (1,873,556 | ) |

The accompanying notes are an integral part of these unaudited interim condensed financial statements.

Annex A-3

NLS PHARMACEUTICS LTD.
UNAUDITED INTERIM CONDENSED STATEMENTS OF
CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
FOR THE SIX MONTHS ENDED JUNE 30, 2025, AND 2024

|